Ocugen, INC

Ocugen reports significant progress in its gene therapy pipeline for blindness diseases, including FDA clearance for a Phase 3 trial and a substantial financing round.

Ocugen, Inc. has signed a binding term sheet with Roots Pharmaceutical for the exclusive rights to its OCU400 gene therapy in the Middle East and North Africa.

Ocugen, Inc. successfully concluded its 2026 Annual Meeting, confirming director elections, auditor ratification, and executive compensation frequency.

Ocugen, Inc. announced the resignation of its Chief Accounting Officer, Ramesh Ramachandran, effective May 29, 2026, with CFO Rita Johnson-Greene appointed as the principal accounting officer.

Ocugen, Inc. reported the departure of its Chief Medical Officer, Huma Qamar, and the appointment of Mohamed Genead as Acting/Interim Chief Medical Officer, effective May 8, 2026.

Ocugen, Inc. announced the completion of its private offering of $115 million in 6.75% Convertible Senior Notes due 2034, with net proceeds of approximately $99.5 million.

Ocugen, Inc. filed its Q2 2026 Form 10-Q, detailing ongoing clinical development and significant net losses, leading to substantial doubt about its ability to continue as a going concern.

Ocugen reported increased net losses and a going concern warning, despite pipeline progress and a new licensing deal, as a merger agreement terminated.

Ocugen, Inc. reported increased net losses for Q2 2025, citing substantial doubt about its going concern ability, while advancing multiple gene therapy programs and announcing a NeoCart business merger.

Ocugen's Q1 2025 results show increased revenue but a larger net loss, with ongoing clinical trial advancements overshadowed by concerns about the company's ability to continue as a going concern.

Ocugen's Q3 2024 report reveals a net loss of $12.97 million, alongside progress in clinical trials and a recent debt financing transaction.

Ocugen's Q2 2024 report highlights progress in its gene therapy programs, including the initiation of a Phase 3 trial for OCU400, while also addressing financial challenges and a material weakness in internal controls.

Ocugen, Inc. reported increased net losses and a going concern warning for 2025, despite advancing its gene therapy pipeline with positive clinical data and regulatory milestones.

Ocugen's 2024 10-K filing highlights progress in gene therapy programs, vaccine development, and provides a detailed overview of the company's financial condition and future strategies.

Ocugen has filed an amendment to its annual report to include information on directors, executive compensation, and corporate governance, as the company will not file its definitive proxy statement within the required timeframe.

Ocugen, Inc. released its 10-K filing, which included a restatement of previous financials and updates on its pipeline, including a Phase 3 trial initiation for OCU400.

Ocugen, Inc. Chief Financial Officer Treerita Johnson-Greene acquired 21,000 shares of common stock on June 15, 2026.

Ocugen, Inc. Director Kompella Uday was granted stock options for 170,100 shares of common stock.

Ocugen, Inc. reports that Director Chandrasekhar Satishchandran acquired stock options, indicating a potential long-term commitment to the company.

Ocugen, Inc. reports that Director Kirsten Castillo was granted stock options to purchase 170,100 shares of common stock at an exercise price of $1.22 per share.

Ocugen, Inc. reports that Director Zhang Junge acquired stock options for 170,100 shares of common stock.

Ocugen, Inc. reports that Director Blaise Coleman was granted stock options for 170,100 shares with an exercise price of $1.22.

Ocugen is holding a special meeting on September 21, 2026, to seek shareholder approval to amend its charter to increase the number of authorized common stock shares by 250 million.

Ocugen provides an update on its gene therapy programs, clinical trial progress, and upcoming annual meeting of stockholders.

Ocugen, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Ocugen is advancing its ophthalmology clinical programs, with a focus on modifier gene therapy and aiming for three Biologics License Applications (BLA) filings in the next three years.

Ocugen's upcoming annual meeting will proceed with a revised agenda following Ernst & Young's decision to decline re-election as the company's independent auditor.

Ocugen's proxy statement outlines proposals for the upcoming annual meeting, including limiting officer liability, increasing authorized shares, and adjusting voting requirements.

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 3.0% in Ocugen, Inc., holding 10,000,000 shares and warrants.

State Street Corporation has reported a beneficial ownership of 6.3% in Ocugen Inc. common stock as of June 30, 2026.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 5.2% of Ocugen, Inc.'s common stock.

The Vanguard Group reported a 5.27% beneficial ownership stake in Ocugen Inc's common stock as of December 31, 2025, in a Schedule 13G filing.

Janus Henderson Group plc has reported a 6.0% beneficial ownership stake in Ocugen, Inc., holding 20 million shares of common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.87% beneficial ownership stake in Ocugen Inc's common stock.